2024
article
OpenAlex
Markus Braun‐Falco
Background: Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase 2 study in patients with systemic lupus erythematosus (SLE), baricitinib 4 mg significantly …
2024
article
OpenAlex
Markus Braun‐Falco
Background: Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase 2 study in patients with systemic lupus erythematosus (SLE), baricitinib 4 mg significantly …
Accès ouvert
2023
article
OpenAlex
Markus Braun‐Falco
Wissenstransfer zu Fonseca LPC, Haddad GR, Bastos LMH, Miola AC, Schmitt JV. Curettage and electrocoagulation versus conventional surgery for treatment of low-risk basal cell carcinoma: A randomized study. Int J Dermatol. 2023 Mar;62(3):e128-e129.Das Basalzellkarzinom (BCC) ist in Mitteleuropa der häufigste Tumor des …
2022
article
OpenAlex
Markus Braun‐Falco
Lentigo maligna ist eine Variante eines Melanoma in situ, die vorrangig in lichtexponierten Arealen älterer Menschen auftritt. Therapeutischer Goldstandard ist die Exzision. Als Alternative wird die Lokaltherapie mittels Imiquimod seit längerem erprobt. Dazu führten Lallas und Kollegen eine retrospektive MulticenterStudie mit 149 …
2022
book-chapter
OpenAlex
Markus Braun‐Falco
2022
book-chapter
OpenAlex
Markus Braun‐Falco
2022
book-chapter
OpenAlex
Markus Braun‐Falco
2022
article
OpenAlex
Markus Braun‐Falco
Importance: Bullous pemphigoid is a difficult-to-treat autoimmune blistering skin disease that predominantly affects older adults and is associated with an increased mortality rate. Objective: To examine the safety and therapeutic potential of nomacopan, an inhibitor of leukotriene B4 and complement C5, in …
2021
article
OpenAlex
Markus Braun‐Falco
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who …
2021
book-chapter
OpenAlex
Markus Braun‐Falco
2021
article
OpenAlex
Markus Braun‐Falco
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who …
2021
article
OpenAlex
Markus Braun‐Falco
The demographic trend of an ageing society is mirrored in the rising number of hospitalized geriatric patients in Germany. However, there is still a wide gap of knowledge regarding the dermatological diseases, comorbidities and performed procedures within this growingly important group of …